23 Feb Gyroscope
Nadia Waheed, M.D., Chief Medical Officer
Our ultimate goal is to slow, or possibly stop, the progression of dry-AMD. Patients in our Phase I/II clinical trial, known as the FOCUS study, receive a single dose of GT005 through an injection below their retina. Syncona, our lead investor, helped us create the only retinal gene therapy company to combine discovery research, drug development, a manufacturing platform and surgical delivery capabilities. Headquartered in London, UK, with locations in Philadelphia and San Francisco, our mission is to preserve sight and fight the devastating impact of blindness.